Molecular Docking of Novel mPGES-1 Inhibitors

Abstract

"Nonsteroidal anti- inflammatory drugs (NSAIDs) are the current treatment for inflammation; however, NSAIDs have led to severe cardiovascular and gastrointestinal side effects. Therefore, there is a significant need for next generation anti-inflammatory drugs that do not present these same side effects. This poster is focused on molecular docking studies of compounds as potential inhibitors of a microsomal prostaglandin E2 (mPGES- 1), a specific enzyme within the inflammatory pathway known to prevent these severe side effects. The top docking scores will then be compared to biological data, which will lead to a structure-activity relationship that will be applied to further analogue design."